Listed

American Vanguard Corp: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 2, 2016 and accepted by EDGAR at Nov 2, 2016, 16:02 ET.

Share

Management's discussion and analysis

As filed, 42,539 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information on risk factors arising during the reporting period, refer to Item 1A., Risk Factors. For more detailed information on risk factors affecting the Company generally, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

MANAGEMENT OVERVIEW

Overall financial performance for the quarter ended September 30, 2016 included sales of $82,447 which were up approximately 14%, as compared to sales of $72,486 for the third quarter of 2015. Our gross profit performance ended at $32,986 or 40% of sales, as compared to $31,433 or 43% of sales for the comparable quarter last year. Gross margin was impacted by a shift in timing to Q3 2016, of some international toll manufacturing which occurred earlier in the season in 2015, and a short term cost increase for a key raw material for one of our international products. Operating costs in the quarter improved from 36% of sales in 2015 to 34.3% of sales this year; notwithstanding this improvement, costs did increase as we continue to develop our international footprint and invest in future business and product development. Overall net income was up at $0.10 per share as compared to $0.09 per share this time last year.

Financial performance for the nine month period ended September 30, 2016 included improved sales and net income, as compared to the same period in 2015. Sales for the period were up approximately 9% to $224,645, as compared to $205,574 for the first nine months of 2015. Under absorption of factory costs for the nine month period reduced from 5% of sales to 4% of sales. Our gross profit performance ended at $91,884 or 41% of sales, as compared to $81,204 or 40% of sales for the comparable prior period. Operating expenses reduced from 36% of net sales to 34% and net income improved by 147% to $0.30 per share, as compared to $0.12 per share.

When considering the balance sheet, net debt reduced by $5,088 in the three month ended September 30, 2016 to $44,488. This compares with $68,321 at December 31, 2015 and $92,731 at the same time last year. Inventory ended the quarter at $141,678, which is in line with our sales and inventory planning for the 2016. In comparison, inventory at this time last year was $161,496. We remain on track for our forecast at December 31, 2016.

RESULTS OF OPERATIONS

Quarter Ended September 30:

Net sales: 2016 2015 Change % Change
Insecticides $25,478 $23,539 $1,939 8.2%
Herbicides/soil fumigants/fungicides 34,242 32,682 1,560 4.8%
Other, including plant growth regulators 13,328 7,420 5,908 79.6%
Total crop 73,048 63,641 9,407 14.8%
Non-crop 9,399 8,845 554 6.3%
Total net sales $82,447 $72,486 $9,961 13.7%
Cost of sales:
Insecticides $17,029 $14,240 $2,789 19.6%
Herbicides/soil fumigants/fungicides 18,146 17,953 193 1.1%
Other, including plant growth regulators 9,609 4,005 5,604 139.9%
Total crop 44,784 36,198 8,586 23.7%
Non-crop 4,677 4,855 (178) -3.7%
Total cost of sales $49,461 $41,053 $8,408 20.5%
Gross profit:
Insecticides $8,449 $9,299 $(850) -9.1%
Herbicides/soil fumigants/fungicides 16,096 14,729 1,367 9.3%
Other, including plant growth regulators 3,719 3,415 304 8.9%
Gross profit crop 28,264 27,443 821 3.0%
Gross profit non-crop 4,722 3,990 732 18.3%
Total gross profit $32,986 $31,433 $1,553 4.9%
Gross margin crop 39% 43%
Gross margin non-crop 50% 45%
Total gross margin 40% 43%
Net sales: 2016 2015 Change % Change
US $60,033 $53,167 $6,866 12.9%
International 22,414 19,319 3,095 16.0%
Total net sales $82,447 $72,486 $9,961 13.7%

For the three months ended September 30, 2016, sales for our Crop business were up approximately 15% at $73,048, as compared to $63,641 for the same period of the prior year, while sales for non-crop products were up 6% at $9,399, as compared to $8,845 last year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Third quarter 2016 financial performance was influenced by some key factors. First, we recorded strong quarterly sales of several of our cotton products due to increased cotton acres this season, up approximately 17% overall and over 50% in the MidSouth region, which is one of our key Folex markets. Second, we enjoyed increased sales of our market leading soil fumigant products primarily used in the late summer and fall periods. Third, our tolling business sales were strong in the third quarter of this year, whereas in the prior year these sales occurred in an earlier period.

Sales of our Insecticide group for crop applications were up 8%, to $25,478, as compared to $23,539 for the third quarter of 2015. The increase was led by sales of Mocap and Nemacur which were up 22% compared to the prior year, offset by Thimet sales that suffered from unfavorable weather conditions in the Southeast U.S.

Within the group of Herbicides/Fungicides/Fumigants, sales for the third quarter of 2016 increased by approximately 5% to $34,242, as compared to $32,682 in the same period of 2015. The main driver was sales of our soil fumigants which rose in the third quarter as post-harvest, on-ground applications in the Southeast and Northwest sections of the U.S. caught up from a slow start last quarter.

Within the group of Other products (which includes plant growth regulators, molluscicides and tolling activity), our sales increased about 80% to $13,328, as compared to $7,420 in the third quarter of 2015. There were two main drivers for this performance. First, toll manufacturing activity increased significantly in the third quarter as compared to 2015 as a result of production scheduling (these annual tolling sales were recorded in the second quarter in 2015). Second, we experienced an increase in purchases of our Folex® cotton defoliant during the quarter, as cotton growers shifted their procurement of this harvest aid closer to time of use in the September/October harvest.

Our Non-crop sales ended the third quarter of 2016 at $9,399, which was 6% above sales of $8,845 for the same period of the prior year. This sales increase was primarily driven by improved sales of our Metaldehyde granules.

On a regional basis, our domestic US sales improved by 13% to end at $60,033 for the three months of 2016, as compared to $53,167 in the same period of 2015. As detailed above, the growth in domestic sales quarter over quarter was largely driven by growth in sales of our Metam fumigants, our Folex cotton defoiliant and our Dacthal herbicide. During the same period, our international sales were up 16% to end at $22,414, as compared to $19,319 for the prior year. International sales increased because of tolling revenues, that occurred in an earlier period in 2015, and increased Nemacur sales, offset by lower sales of Dacthal where we had a schedule delay in formulating a specific item resulting in sales probably moving to later in the year.

Our cost of sales for the third quarter of 2016 was $49,461 or 60% of sales, as compared to $41,053 or 57% of sales for the same period of 2015. There were a number of factors driving the increase. First, our tolling revenues occurred in the second quarter of 2015, whereas this year they occurred in the third quarter. This mix change impacts our overall cost of sales by 1.4%. Second, during the quarter we experienced a temporary price increase for a raw material that is used in an international product line. That increase impacted our overall cost of sales by 1.6%. We expect that we will work through the higher priced raw material and return to more normal margins for this product by the end of the second quarter of 2017. Our labor and burden costs increased as we expanded manufacturing output in the three months ended September 30, 2016, as compared to the same period of the prior year. Partly offsetting these factors, we have enjoyed cost reduction on a number of key raw materials.

Gross margin ended the quarter at 40% for the three months ended September 30, 2016, as compared to 43% in the same period of the prior year. The change in margin percentage was expected primarily because of the shift in international tolling revenues and is detailed above in the cost of sales discussion.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by $2,196 to $28,255 for the three months ended September 30, 2016, as compared to the same period in 2015. The differences in operating expenses by department are as follows:

2016 2015 Change % Change
Selling $7,065 $6,493 $572 8.8%
General and administrative 7,546 6,980 566 8.1%
Research, product development and regulatory 5,200 4,494 706 15.7%
Freight, delivery and warehousing 8,444 8,092 352 4.3%
$28,255 $26,059 $2,196 8.4%
  • Selling expenses increased $572 over the same quarter of the prior year. The main driver for the increase is from the further development of our international business.
  • General and administrative expenses increased by $566. The main drivers are increased incentive compensation, as a result of our improved financial performance and increased legal expense.
  • Research, product development costs and regulatory expenses increased by $706. In the three months ended September 30, 2016, we increased our spending on regulatory compliance, field trials for product development and our SIMPAS development project.
  • Freight, delivery and warehousing costs increased by $352. As a percentage of sales, freight costs improved to 10.3% of sales for the three months ended September 30, 2016, as compared to 11.0% for the same period of the prior year.

Interest costs, net of capitalized interest were $301 in the three months to September 30, 2016 as compared to $638 in the same period of 2015. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

Q3 2016 Average Debt Interest Expense Interest Rate Q3 2015 Average Debt Interest Expense Interest Rate
Average revolving line of credit $44,617 $241 2.2% $88,826 $498 2.2%
Notes payable 9 — — 10,081 101 —
Amortization of deferred loan fees — 62 — — 62 —
Amortization of other deferred liabilities — 9 — — 29 —
Other interest expense — 11 — — 10 —
Subtotal $44,626 $323 2.9% $98,907 $700 2.8%
Capitalized interest — (22) — — (62) —
Total $44,626 $301 2.7% $98,907 $638 2.6%

The Company’s average overall debt for the three months ended September 30, 2016 was $44,626, as compared to $98,907 for the three months ended September 30, 2015. Included in interest expense of $301 during the three months ended September 30, 2016, are non-cash costs related to amortization of discounting for deferred payments and other interest expense, net of capitalized interest, in the amount of $22 as compared to $62 for the same period of the prior year. The effective rate on our bank borrowings was flat at 2.2% for the period to September 30, 2016 and the same period of the prior year. Our overall effective interest rate was 2.7% for the three months ended September 30, 2016, as compared to 2.6% at September 30, 2015.

For the three months ended September 30, 2016, income tax expense totaled $1,409 and the effective tax rate for the quarter was 31.8%. These amounts are based upon management’s estimates for the full fiscal year, which are subject to review and revision. For the three months ended September 30, 2015, income tax expense totaled $1,643 and the effective tax rate for the quarter was 34.7%.

Our overall net income for the three months ended September 30, 2016 totaled $2,877 or $0.10 per diluted share as compared to $2,772 or $0.09 per diluted share in the same quarter of 2015.

Nine Months Ended September 30:

Net sales: 2016 2015 Change % Change
Insecticides $89,496 $85,484 $4,012 4.7%
Herbicides/soil fumigants/fungicides 80,009 71,973 8,036 11.2%
Other, including plant growth regulators 23,148 23,497 (349) -1.5%
Total crop 192,653 180,954 11,699 6.5%
Non-crop 31,992 24,620 7,372 29.9%
Total net sales $224,645 $205,574 $19,071 9.3%
Cost of sales:
Insecticides $59,244 $55,244 $4,000 7.2%
Herbicides/soil fumigants/fungicides 42,907 41,139 1,768 4.3%
Other, including plant growth regulators 15,184 14,372 812 5.6%
Total crop 117,335 110,755 6,580 5.9%
Non-crop 15,426 13,615 1,811 13.3%
Total cost of sales $132,761 $124,370 $8,391 6.7%
Gross profit:
Insecticides $30,252 $30,240 $12 0.0%
Herbicides/soil fumigants/fungicides 37,102 30,834 6,268 20.3%
Other, including plant growth regulators 7,964 9,125 (1,161) -12.7%
Gross profit crop 75,318 70,199 5,119 7.3%
Gross profit non-crop 16,566 11,005 5,561 50.5%
Total gross profit $91,884 $81,204 $10,680 13.2%
Gross margin crop 39% 39%
Gross margin non-crop 52% 45%
Total gross margin 41% 40%
Net sales: 2016 2015 Change % Change
US $161,661 $146,231 $15,430 10.6%
International 62,984 59,343 3,641 6.1%
Total net sales $224,645 $205,574 $19,071 9.3%

For the nine months ended September 30, 2016, sales for our Crop business were $192,653, up approximately 7% from $180,954 in 2015, while sales for Non-crop products were $31,992, up by about 30% from $24,620 in the comparable period of the prior year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

During the period, the Company experienced an 18% increase in sales of its corn products (including our Impact® herbicide and our granular corn insecticides). In addition, during the 2015-16 growing season which ended on September 30, 2016, channel inventories of the same products have reduced by approximately 20%. The Company has also seen significant growth in sales associated with the Bromacil and European Nemacur acquisitions, concluded early in 2015, the Scepter license, signed in the late fall of 2015 and in revenues from a third party for the exclusive right for licenses to certain of our natural oil products.

Net sales of our Insecticides used in crop applications for the nine months ended September 30, 2016 were about 5% higher at $89,496, as compared to $85,484 during the same period of 2015. Within this category, sales of our granular soil insecticides (“GSIs”) were up approximately 3% as compared to the same period in 2015, primarily driven by increased sales of Nemacur. Sales of our non-GSI insecticides for crop applications were led by higher year-to-date sales of Bidrin and Bifenthrin, our primary cotton insecticides.

Within the group of Herbicides/Fungicides/Fumigants for crop applications, sales for the first nine months of 2016 were $80,009, approximately 11% higher than the $71,973 recorded in the first nine months of 2015. While sales of our soil fumigant products declined slightly as a result of some weather-related wet field application difficulties, sales of herbicides increased significantly driven by strong Impact sales in U.S. corn, the addition of Scepter the portfolio, and stronger sales of Bromacil as that product line was more fully integrated into our international business.

Within the group of Other products (which includes plant growth regulators, molluscicides and tolling activity), we recorded net sales of $23,148, as compared to $23,497 in the first three quarters of 2015. Sales in all of the above categories were relatively flat compared with the prior year nine month performance.

Our Non-crop sales for the first nine months of 2016 were $31,992, up 30% from $24,620 for the same period of the prior year. This performance was driven by our pest strip, pharmaceutical and Envance sales that were all considerably higher in the first nine months of 2016, as compared to the similar period in 2015. Pest strips sales were up because one of our major customers made the decision to purchase a multiyear order in December 2014 in order to secure a price point. That customer inventory cleared out in early 2016. Normal replenishment is now on-going. Pharmaceutical sales improved because of forecast product supply interruption in 2017 related to a specific raw material supplier in the Czech Republic that has decided to exit the market. New suppliers have been found but the approval process will take time and as a result there will be a gap in supply. Customers are making decisions this year to insulate themselves during that possible gap period by increasing their order size. Envance revenues are being driven by proceeds from licensed rights to our natural oil products, in certain markets; this license arrangement was not in place in 2015.

On a regional basis, our domestic US sales improved by 11% to end at $161,661 for the first three quarters of 2016, as compared to $146,231 in the same period of 2015. The drivers are performance in the corn market, the revenues from license rights to our natural oil products, strong domestic sales of Dacthal and revenues related to the Scepter license. During the same period, our international sales were up 6% to end at $62,984, as compared to $59,343 for the prior year. The main drivers were increased revenues from Bromacil and European sales of Nemacur acquired early in 2015, offset (to a degree) by lower international sales of Dacthal as a result of a short term formulating capacity issue that should resolve during the final quarter of the year.

Our cost of sales for the nine months of 2016 was $132,761 or 59% of net sales. This compared to $124,370 or 60% of net sales for the same period of 2015. The main drivers for the change were improvements generated by revenues for license rights to our natural oil products offset by the short term issue, primarily affecting the third quarter, related to raw material costs for an international product line.

Our labor and burden costs were 1% lower in the nine months ended September 30, 2016, as compared to the same period of the prior year. Further, as our channel inventories have reduced, we have been slowly ramping up production of some products resulting in improved factory cost recovery, as compared to the first nine months of 2015. These improvements resulted in reduced net factory costs which amounted to 4% (of sales) in the nine months of 2016, as compared to 5% in the same period of 2015 and added $1,662 to our gross profit performance in the nine months of 2016, as compared to this time last year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by $3,104 to $77,429 for the nine months ended September 30, 2016, as compared to the same period of 2015. The differences in operating expenses by department are as follows:

2016 2015 Change % Change
Selling $19,597 $20,638 $(1,041) -5.0%
General and administrative 23,263 20,389 2,874 14.1%
Research, product development and regulatory 15,995 14,771 1,224 8.3%
Freight, delivery and warehousing 18,574 18,527 47 0.3%
$77,429 $74,325 $3,104 4.2%
  • Selling expenses for the period decreased by $1,041. The main drivers for the overall decrease in selling expenses were lower spending on advertising and promotional activities.
  • General and administrative expenses increased by $2,874. The main drivers are increases in incentive compensation, intangible asset amortization associated with product acquisitions in 2015, and additional legal expenses.
  • Research, product development costs and regulatory expenses increased by $1,224. The main drivers were increased costs incurred in our spending on regulatory compliance, field trials for product development and our SIMPAS development project.
  • Freight, delivery and warehousing costs for the nine months ended September 30, 2016 were $18,574 or 8.2% of sales as compared to $18,527 or 9.0% of sales for the same period in 2015. The main driver for the decrease (as a percentage of sales) is related to the increase in sales of products with low freight costs and products where buyers bear freight charges.

Interest costs net of capitalized interest, were $1,304 in the nine months of 2016, as compared to $1,941 in the same period of 2015. Interest costs are summarized in the following table:

Average Indebtedness and Interest expense

Nine months ended September 30, 2016 Average Debt Interest Expense Interest Rate Nine months ended September 30, 2015 Average Debt Interest Expense Interest Rate
Average revolving line of credit $63,949 $1,098 2.3% $100,292 $1,541 2.0%
Notes payable 27 1 — 5,834 170 —
Interest Income — (1) — — (1) —
Amortization of deferred loan fees — 187 — — 228 —
Amortization of other deferred liabilities — 28 — — 114 —
Other interest expense — 36 — — 38 —
Subtotal $63,976 $1,349 2.8% $106,126 $2,090 2.6%
Capitalized interest — (45) — — (149) —
Total $63,976 $1,304 2.7% $106,126 $1,941 2.4%

The Company’s average overall debt for the nine months ended September 30, 2016 was $63,976 as compared to $106,126 for the same period of 2015. During the nine months ended September 30, 2016, the Company remained focused on driving down the revolving debt following the 2015 product acquisitions. Included in interest expense of $1,304 during the nine months ended September 30, 2016, are non-cash costs related to amortization of discounting of deferred payments and other interest expense in the amount of $206, as compared to $400 for the same period of the prior year. The effective rate on our bank borrowings was 2.3% for the period to September 30, 2016, as compared to 2.0% for the same period of the prior year. Our overall effective interest rate was 2.7% for the nine months ended September 30, 2016, as compared to 2.4% in the same period of 2015.

For the nine months ended September 30, 2016, income tax expense increased by $2,714 to end at $3,672 and the effective tax rate was 27.9%. The amount is based upon management’s estimates for the full fiscal year, which are subject to review and revision. For the nine months ended September 30, 2015, income tax expense totaled $958 and the effective tax rate was 19.4%. The change in effective tax rate is primarily driven by improved year on year earnings in jurisdictions with higher income tax rates.

Our overall net income attributable to American Vanguard for the nine months of 2016 was $8,917 or $0.30 per diluted share, as compared to $3,604 or $0.12 per diluted share in the same period of 2015.

LIQUIDITY AND CAPITAL RESOURCES

The Company generated $36,200 of cash in operating activities during the nine months ended September 30, 2016. This compares to generating $51,807 in the same period of last year. Net income of $9,170, non-cash depreciation and amortization of fixed and intangible assets, other assets and discounted future liabilities in the amount of $16,330, stock based compensation expense of $1,656 plus a non cash loss recorded on our equity investment and tax benefit from exercise of stock options provided a net cash inflow of $27,383 as compared to $23,215 for the same period last year.

During the nine months ended September 30, 2016, the Company increased trade receivables by $19,202. This compares with an increase in trade receivables of $6,172 during the same period of 2015. The movement in receivables is primarily driven by strong domestic sales in the later part of the period to September 30, 2016.

At the end of September 2016, our inventories were at $141,678, which was down from $161,496 at this time last year. In comparison to the start of the financial year, our inventories have increased by $5,201 in the nine month period of 2016, as compared to decreasing by $4,135 during the same period of the prior year. This 2016 performance reflects the improving condition of channel inventory levels of the Company’s products which is allowing us to start slowly increasing the manufacturing level for some products as we look forward to the 2016-2017 season. As of September 30, 2016, we believe our inventories are valued at lower of cost or market.

During the nine months ended September 30, 2016, deferred revenues decreased by $8,847, as compared to a decrease of $860 for the same period of the prior year. The decrease in deferred revenues reflects customers utilizing their prepayments made in prior periods.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the nine months ended September 30, 2016, the Company made accruals in the amount of $45,456. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. However, there are some programs that are paid more frequently or that have different settlement dates that reflect particular growing seasons. During the first nine months of 2016, the Company made payments in the amount of $14,920. Payments are not generally significant in the second and third quarters of each financial year. During the nine months ended September 30, 2015, the Company accrued $38,102 and made payments in the amount of $17,120.

Finally, prepaid and other assets increased by $1,011, tax payable increased by $1,519, accounts payable increased by $7,925, and other payables and accruals increased by $3,098. In aggregate, this amounted to a $11,531 inflow. During the same period of 2015, these items amounted to a $10,507 inflow.

The Company is working to manage its capital spending closely and utilized $6,122 during the nine months ended September 30, 2016, compared to utilizing $5,196 during the same period of 2015. This is primarily driven by an increase in capital spending in our factories including the capital cost of putting in place a dedicated manufacturing cell at one of the toll manufacturing locations. During the first nine months of 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of September 30, 2016, the Company’s ownership position in Bi-PA was 15%. During the comparable period in 2015, the Company increased its ownership share of its Envance subsidiary by paying $125 to its joint venture partner, TyraTech and, in addition, making a capital contribution to the joint venture in the amount of $1,263. Finally, during the first nine months of 2015, the Company completed two acquisitions of product lines and spent a total of $36,435 on those transactions. During the first nine months of 2016, the Company made final payments associated with the 2015 product acquisitions in the amount of $224.

The Company has a revolving line of credit and a note payable that together constitute the short-term and long-term loan balances shown in the balance sheets at September 30, 2016 and December 31, 2015. These are summarized in the following table:

Indebtedness $000’s September 30, 2016 Long- term Short- term Total December 31, 2015 Long- term Short- term Total
Revolving line of credit $45,000 $— $45,000 $69,000 $— $69,000
Deferred loan fees (512) — (512) (679) — (679)
Notes payable — — — — 55 55
Total Indebtedness $44,488 $— $44,488 $68,321 $55 $68,376

Under the Credit Agreement, the Company has three key covenants (with which it was in compliance throughout the nine months ended September 30, 2016). The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio.

On April 14, 2015, AMVAC, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into an amendment to the Credit Agreement under which, the Consolidated Funded Debt Ratio was increased for the second, third and fourth quarters of 2015 (to 3.5-to-1 from 3.25-to-1) and a fixed charge covenant, requiring, in effect, that the ratio of consolidated current assets to consolidated current liabilities exceed 1.2-to-1 for the duration of the term of the credit facility, was added.

At September 30, 2016, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $95,985 under the credit facility agreement. This compares to an available borrowing capacity of $40,189 as of September 30, 2015. The level of borrowing capacity was driven by three factors: (1) our financial performance, as measured in EBITDA for the trailing twelve month period, has improved, (2) the level of borrowings during the third quarter of 2015 was higher than normal due to the then recent completion of two product line acquisitions, and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement) was lower when compared with the earlier period.

The Company believes that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

RECENTLY ISSUED ACCOUNTING GUIDANCE

Recently Issued Accounting Guidance—In August 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new standard addresses eight specific classification issues within the current practice regarding the manner in which certain cash receipts and cash payments are presented. The new standard is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated statements of cash flows.

In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718). The new standard changes the accounting for certain aspects of share-based payments to employees. The standard requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additional paid in capital (“APIC”) pools. The standard also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. Cash paid by an employer when directly withholding shares for tax-withholding purposes should be classified as a financing activity in the statement of cash flows. In addition, the standard allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The new standard is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In March 2016, FASB issued ASU 2016-07, Investments—Equity Method and Joint Ventures. The new standard eliminates the requirement that an investor retrospectively apply equity method accounting when an investment that it had accounted for by another method initially qualifies for the equity method. The guidance requires that an equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor’s previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The new standard is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In February 2016, FASB issued ASU 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The update provides that equity investments with readily determinable values be measured at fair value and changes in the fair value flow through net income. These changes historically have run through other comprehensive income. Equity investments without readily determinable fair values have the option to be measured at fair value or at cost adjusted for changes in observable prices minus impairment. Changes in either method are also recognized in net income. The standard requires a qualitative assessment of impairment indicators at each reporting period. For financial liabilities, entities that elect the fair value option must recognize the change in fair value attributable to instrument-specific credit risk in other comprehensive income rather than net income. Lastly, regarding deferred tax assets, the need for a valuation allowance on a deferred tax asset will need to be assessed related to available-for-sale debt securities. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In November 2015, FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The standard requires all deferred tax assets and liabilities, as well as any related valuation allowance, to be classified as non-current on the balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and earlier adoption is permitted. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330). Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is currently evaluating the impact of our pending adoption of the new standard on our consolidated financial statements.

In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.

In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of its pending adoption of ASU 2014-09 on the consolidated financial statements and has not yet determined the method by which it will adopt the standard in 2018 or its impact on the consolidated financial statements.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2015, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2015.

Market risk

As filed, 1,252 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2015.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

Controls and procedures

As filed, 1,051 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company has established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of September 30, 2016, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

Risk factors

As filed, 409 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 2, 2016. In preparing this document, we have reviewed all the risk factors included in that document and believe that there are no material changes to those risk factors.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$82.4mus-gaap:SalesRevenueNet
Revenue9 months2016-01-01 to 2016-09-30$224.6mus-gaap:SalesRevenueNet
Cost of revenue3 months2016-07-01 to 2016-09-30$49.5mus-gaap:CostOfRevenue
Cost of revenue9 months2016-01-01 to 2016-09-30$132.8mus-gaap:CostOfRevenue
Gross profit3 months2016-07-01 to 2016-09-30$33.0mus-gaap:GrossProfit
Gross profit9 months2016-01-01 to 2016-09-30$91.9mus-gaap:GrossProfit
Operating income3 months2016-07-01 to 2016-09-30$4.7mus-gaap:OperatingIncomeLoss
Operating income9 months2016-01-01 to 2016-09-30$14.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-07-01 to 2016-09-30$301.0kus-gaap:InterestExpense
Interest expense9 months2016-01-01 to 2016-09-30$1.3mus-gaap:InterestExpense
Income tax3 months2016-07-01 to 2016-09-30$1.4mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2016-01-01 to 2016-09-30$3.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-07-01 to 2016-09-30$2.9mus-gaap:NetIncomeLoss
Net income9 months2016-01-01 to 2016-09-30$8.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-07-01 to 2016-09-30$0.10us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2016-01-01 to 2016-09-30$0.30us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-07-01 to 2016-09-30$0.10us-gaap:EarningsPerShareBasic
Basic EPS9 months2016-01-01 to 2016-09-30$0.31us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-07-01 to 2016-09-3029,496,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2016-01-01 to 2016-09-3029,385,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2016-01-01 to 2016-09-30$36.2mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure9 months2016-01-01 to 2016-09-30$224.0kus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid9 months2016-01-01 to 2016-09-30$289.0kus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2016-09-30$6.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$263.2mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$463.1mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$109.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$184.8mus-gaap:Liabilities
Long-term debtAt period end2016-09-30$44.5mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2016-09-30$0us-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2016-09-30$278.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-16-026972. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.